ClinicalTrials.gov
ClinicalTrials.gov Menu

Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy (BIBC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01652560
Recruitment Status : Unknown
Verified July 2012 by LiNanlin,Ph.D, Chief Physician,Clinical Professor, Xijing Hospital.
Recruitment status was:  Recruiting
First Posted : July 30, 2012
Last Update Posted : July 30, 2012
Sponsor:
Collaborator:
Roche Pharma AG
Information provided by (Responsible Party):
LiNanlin,Ph.D, Chief Physician,Clinical Professor, Xijing Hospital

July 21, 2012
July 30, 2012
July 30, 2012
June 2012
June 2014   (Final data collection date for primary outcome measure)
Objective Response Rate [ Time Frame: From enrollment to disease progression ]
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years.
Same as current
No Changes Posted
overall response [ Time Frame: From enrollment to disease progression ]
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years.
Same as current
Not Provided
Not Provided
 
Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy
Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy
- The purpose of this study is to evaluate the efficacy and safety of the application of bevacizumab combined neoadjuvant chemotherapy in HER2-negative breast cancer.
Not Provided
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Breast cancer patients of vascular endocrine surgery department in Xijing Hospital
  • Breast Cancer
  • Bevacizumab
  • Neoadjuvant Chemotherapy
  • Molecular Targeted Therapy
Drug: bevacizumab
The patients will be treated with Avastin combined neoadjuvant chemotherapy
Other Name: Avastin
bevacizumab combined neoadjuvant chemotherapy
Intervention: Drug: bevacizumab
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
50
Same as current
September 2014
June 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • HER2-negative breast cancer patients
  • Without surgery
  • Plans to neoadjuvant chemotherapy

Exclusion Criteria:

  • HER2-positive breast cancer patients
  • Post-operative patients
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
China
 
 
NCT01652560
QTDS-01
No
Not Provided
Not Provided
LiNanlin,Ph.D, Chief Physician,Clinical Professor, Xijing Hospital
LiNanlin,Ph.D, Chief Physician,Clinical Professor
Roche Pharma AG
Not Provided
Xijing Hospital
July 2012